Stage III Bladder Urothelial Carcinoma AJCC v6 and v7

8 clinical trials · Condition

Record	Firm	Date
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer (NCT03419130)	University of California, San Francisco	2018-07-18
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo (NCT03421652)	Barbara Ann Karmanos Cancer Institute	2018-04-24
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (NCT03244384)	National Cancer Institute (NCI)	2017-11-03
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (NCT03047213)	National Cancer Institute (NCI)	2017-08-24
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery (NCT02812420)	M.D. Anderson Cancer Center	2017-03-07
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (NCT02178241)	National Cancer Institute (NCI)	2014-12-11

Every clearance here is in the API, with alerts when new ones post.